Edgar Filing: CORCEPT THERAPEUTICS INC - Form 4

CORCEPT THERAPEUTICS INC

Form 4

August 23, 2007

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

OMB Number:

3235-0287

January 31,

Expires:

2005

0.5

burden hours per

Estimated average

OMB APPROVAL

response...

Check this box if no longer subject to Section 16. Form 4 or Form 5

SECURITIES

obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person *

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to

Issuer

MARDUEL ALIX

CORCEPT THERAPEUTICS INC [CORT]

(Check all applicable)

(Last)

(First)

(Middle)

3. Date of Earliest Transaction

X Director Officer (give title below)

10% Owner Other (specify

ONE EMBARCADERO CENTER, SUITE 3700

4. If Amendment, Date Original

(Month/Day/Year)

08/17/2007

6. Individual or Joint/Group Filing(Check Applicable Line)

Filed(Month/Day/Year)

X Form filed by One Reporting Person Form filed by More than One Reporting

SAN FRANCISCO, CA 94111

(Street)

(City) (State) (Zip) 1. Title of 2. Transaction Date 2A. Deemed Security (Month/Day/Year) Execution Date, if

3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 5. Amount of Securities Beneficially Owned Following

6. 7. Nature of Ownership Indirect Form: Direct Beneficial (D) or Ownership Indirect (I) (Instr. 4)

(Instr. 4)

Reported Transaction(s) (Instr. 3 and 4)

Code V Amount

or Price (D)

(A)

See

Stock

Common

(Instr. 3)

(1) 08/17/2007

952,381 P (2)

 $4,150,655 \stackrel{(2)}{=}$ 2.1 (3)

footnotes (2)(3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

(Month/Day/Year)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: CORCEPT THERAPEUTICS INC - Form 4

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exerc	cisable and	7. Title	e and	8. Price of	9. Nu
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orNumber	Expiration D	ate	Amou	nt of	Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Under	lying	Security	Secui
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Securi	ties	(Instr. 5)	Bene
	Derivative				Securities			(Instr.	3 and 4)		Owne
	Security				Acquired						Follo
	·				(A) or						Repo
					Disposed						Trans
					of (D)						(Instr
					(Instr. 3,						`
					4, and 5)						
					, ,						
									Amount		
						Date	Expiration		or		
						Exercisable	Date	Title IN	Number		
									of		
				Code V	(A) (D)				Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
MARDUEL ALIX ONE EMBARCADERO CENTER SUITE 3700 SAN FRANCISCO, CA 94111	X	X					

Signatures

Reporting Person

Alix Marduel,
Director

**Signature of
Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) N/A

Alta Partners II, Inc. ("APII") provides investment advisory services to several venture capital funds including Alta BioPharma Partners II, L.P. ("ABPII") & Alta Embarcadero BioPharma Partners II, LLC ("AEBPII"). On 8/17/07, ABPII purchased 918,589 shares ("sh") of Common Stock ("Cm") & AEBPII purchased 33,792 sh Cm from the Company in conjunction with the Common Stock Purchase

- (2) Agreement dated 8/17/07. As a result of this purchase, ABPII beneficially owns 3,997,378 sh Cm & AEBPII beneficially owns 153,277 sh Cm. The managing directors ("md") of ABPII & managers of AEBPII exercise sole voting & investment power with respect to the sh owned by such funds. They disclaim beneficial ownership of all such sh held by the foregoing funds, except to the extent of their proportionate pecuniary interests therein.
- Alix Marduel, Director, is a managing director ("md") of Alta BioPharma Management II, LLC ("ABPMII")(which is the general partner of ABPII) and a manager of AEBPII. As a md of ABPMII (which is the general partner of ABPII) & a manager of AEBPII, she may be deemed to share voting & investment powers for the sh held by the funds. She disclaims beneficial ownership of all such shares held by the foregoing funds, except to the extent of her proportionate pecuniary interests therein.

Remarks:

Cross-reference with Form 3 dated 8/17/2007 filed on behalf of Alta BioPharma Management II, LLC on 8/20/2007. Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Reporting Owners 2

Edgar Filing: CORCEPT THERAPEUTICS INC - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.